Description
Hypothemycin (76958-67-3) is a potent and selective inhibitor of MEK.1-3Acts via covalent binding to Cys residue.2In cells, hypothemycin inhibits the MEK-ERK axis with sufficient selectivity to normalize transformed phenotypes3. Inhibits TNFα production in LPS-stimulated macrophages.4
Uses
Hypothemycin is a potent and selective inhibitor of threonine/tyrosine-specific kinase, MEK, and other protein kinases that contain a conserved cysteine residue in the ATP-binding site in in vitro studies.
General Description
A cell-permeable
cis-enone resorlic acid lactone (RAL) and (5
Z)-7-Oxozeaenol (Cat. No.
499610) analog that inhibits several kinases via an initial affinity binding to the ATP pocket, followed by a covalent adduct formation with a conserved ATP site cysteine residue of the targeted enzymes, including, but not limited to, Flt1/VEGFR-1, Flt3, cKit(D816V), MAPK1, MAPK2, MEK1, MKK6, PKCμ, PKD2, PRAK, and Tak1 (≥90% inhibition at 2 μM). Hypothemycin is also reported to inhibit two non-RAL targets (99% and 82% inhibition of TrkA and TrkB, respectively, at 2 μM), while one of the 46 putative
cis-enone RALs targets, namely GSK-3α, is shown not to be affected. Hypothemycin inhibits multiple kinases involved in MAP kinase pathways and is therefore particularly effective in inhibiting BRAF(V600E)-dependent tumor growth. (5
Z)-Zeaenol (Cat. No.
499609) may serve as a negative control.
Biochem/physiol Actions
Hypothemycin, one of the highly oxygenated analogues in the group of 14-membered resorcylic acid lactones (RAL), has minor antifungal and cytotoxic activity and exhibits an in vitro anti-malarial activity with an IC50 of 2.2 μg/mL. Hypothemycin is also reported to selectively and irreversibly inhibit protein kinases that contain a conserved cysteine residue (Cys166) that is located within the ATP-binding domain. Though this group accounts for less then 10% of all identified kinases, there are several targets implicated in aberrant cellular proliferation such as ERKs, MEK, FMS-like tyrosine kinase protein (FLT), and platelet-derived growth factor receptors (PDGFR). In cell culture, hypothemycin displays potent cytotoxicity against cancer cell lines that are dependent on certain activating kinase mutations. Additionally, hypothemycin demonstrates significant tumor growth inhibition in at least three separate murine xenograft models. Hypothemycin also inhibits the production of several cytokines such as IL2, IL6, IFNγ, and TNFα.
in vivo
Hypothemycin (10 mg/kg) kills T. brucei in infected mice, completely curing the infection in one third of animals, although high doses of Hypothemycin (>10 mg/kg) leads to side effects[1].
| Animal Model: | Adult female Balb/c mice (weighing 18–22 g) infected with T. brucei[1] |
| Dosage: | 10 mg/kg |
| Administration: | Administered once daily via intraperitoneal injection for 7 days. |
| Result: | Showed a dose-dependent reduction in parasitemia in infected mice.
Prolonged survival of infected mice over 30 days, with a cure rate of 33%. |
IC 50
VEGFR2: 10 nM (Ki); VEGFR1: 70 nM (Ki); MEK1: 17 nM (Ki); MEK2: 38 nM (Ki); FLT-3: 90 nM (Ki); PDGFRα: 1.5 μM (Ki); PDGFRβ: 900 nM (Ki); ERK1: 8.4 μM (Ki); ERK2: 2.4 μM (Ki)
References
[1] A ZHAO. Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK.[J]. Journal of Antibiotics, 1999, 52 12: 1086-1094. DOI:
10.7164/antibiotics.52.1086[2] ANDREAS SCHIRMER. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103 11: 4234-4239. DOI:
10.1073/pnas.0600445103[3] HIDESUKE FUKAZAWA. The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells.[J]. Biological & pharmaceutical bulletin, 2010, 33 2: 168-173. DOI:
10.1248/bpb.33.168[4] KI HWAN PARK . Hypothemycin inhibits tumor necrosis factor-α production by tristetraprolin-dependent down-regulation of mRNA stability in lipopolysaccharide-stimulated macrophages[J]. International immunopharmacology, 2015, 29 2: Pages 863-868. DOI:
10.1016/j.intimp.2015.08.030
